A detailed history of Nuveen Asset Management, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 1,139,142 shares of CPRX stock, worth $23.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,139,142
Previous 830,556 37.15%
Holding current value
$23.5 Million
Previous $12.9 Million 76.03%
% of portfolio
0.01%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.19 - $21.35 $4.69 Million - $6.59 Million
308,586 Added 37.15%
1,139,142 $22.6 Million
Q2 2024

Aug 09, 2024

BUY
$14.68 - $16.92 $3.82 Million - $4.4 Million
260,037 Added 45.58%
830,556 $12.9 Million
Q1 2024

May 13, 2024

BUY
$13.18 - $17.11 $3.98 Million - $5.16 Million
301,807 Added 112.32%
570,519 $9.09 Million
Q4 2023

Feb 14, 2024

BUY
$11.78 - $17.29 $57,451 - $84,323
4,877 Added 1.85%
268,712 $4.52 Million
Q3 2023

Nov 14, 2023

BUY
$11.69 - $15.02 $54,136 - $69,557
4,631 Added 1.79%
263,835 $3.08 Million
Q2 2023

Aug 14, 2023

SELL
$11.5 - $18.08 $61,720 - $97,035
-5,367 Reduced 2.03%
259,204 $3.48 Million
Q1 2023

May 15, 2023

SELL
$14.34 - $21.05 $9.48 Million - $13.9 Million
-661,306 Reduced 71.42%
264,571 $4.39 Million
Q4 2022

Feb 14, 2023

SELL
$12.25 - $19.5 $5.61 Million - $8.93 Million
-457,912 Reduced 33.09%
925,877 $17.2 Million
Q3 2022

Nov 14, 2022

SELL
$7.06 - $15.52 $465,734 - $1.02 Million
-65,968 Reduced 4.55%
1,383,789 $17.8 Million
Q2 2022

Aug 15, 2022

BUY
$6.23 - $8.57 $4.68 Million - $6.44 Million
751,576 Added 107.65%
1,449,757 $10.2 Million
Q1 2022

May 16, 2022

SELL
$5.31 - $8.31 $163,298 - $255,557
-30,753 Reduced 4.22%
698,181 $5.48 Million
Q4 2021

Feb 14, 2022

SELL
$5.21 - $7.45 $382,148 - $546,450
-73,349 Reduced 9.14%
728,934 $4.68 Million
Q3 2021

Nov 12, 2021

SELL
$4.85 - $6.04 $527,107 - $656,439
-108,682 Reduced 11.93%
802,283 $4.05 Million
Q2 2021

Aug 16, 2021

BUY
$4.29 - $6.05 $143,646 - $202,578
33,484 Added 3.82%
910,965 $5.24 Million
Q1 2021

May 17, 2021

SELL
$3.45 - $4.69 $135,750 - $184,542
-39,348 Reduced 4.29%
877,481 $4.05 Million
Q4 2020

Feb 16, 2021

BUY
$2.97 - $3.83 $1.58 Million - $2.04 Million
533,282 Added 139.04%
916,829 $3.06 Million
Q3 2020

Nov 16, 2020

BUY
$2.97 - $5.08 $5,672 - $9,702
1,910 Added 0.5%
383,547 $1.14 Million
Q2 2020

Aug 14, 2020

SELL
$3.48 - $5.05 $61,877 - $89,794
-17,781 Reduced 4.45%
381,637 $1.76 Million
Q1 2020

May 14, 2020

SELL
$2.61 - $5.21 $4.57 Million - $9.12 Million
-1,750,115 Reduced 81.42%
399,418 $1.54 Million
Q4 2019

Feb 14, 2020

BUY
$3.67 - $5.7 $6.42 Million - $9.97 Million
1,748,591 Added 436.12%
2,149,533 $8.06 Million
Q3 2019

Nov 14, 2019

BUY
$3.89 - $7.43 $24,806 - $47,381
6,377 Added 1.62%
400,942 $2.13 Million
Q2 2019

Aug 15, 2019

BUY
$2.7 - $6.11 $1.07 Million - $2.41 Million
394,565 New
394,565 $1.52 Million

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.12B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.